Barzolvolimab Biosimilar – Anti-CD117 mAb – Research Grade

Description of Barzolvolimab Biosimilar - Anti-CD117 mAb - Research Grade

Introduction

Barzolvolimab Biosimilar, also known as Anti-CD117 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Barzolvolimab. This therapeutic antibody targets the CD117 protein, which is a receptor for stem cell factor and is expressed on the surface of various cells, including hematopoietic stem cells and cancer cells. In this article, we will explore the structure, activity, and potential applications of Barzolvolimab Biosimilar as a research-grade antibody.

Structure

Barzolvolimab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced through genetic engineering techniques to be similar to a human antibody. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the ends of the arms and a crystallizable fragment (Fc) at the base. The Fab regions contain the variable regions that bind specifically to the CD117 protein, while the Fc region is responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity

Barzolvolimab Biosimilar binds specifically to the CD117 protein on the surface of cells. This binding blocks the interaction between CD117 and its ligand, stem cell factor, which is essential for the survival and proliferation of hematopoietic stem cells. By inhibiting this interaction, Barzolvolimab Biosimilar can prevent the growth and survival of cancer cells that express CD117, making it a potential therapeutic option for various cancers. Additionally, the Fc region of the antibody can activate immune cells to attack and kill cancer cells through ADCC and CDC mechanisms.

Applications

Barzolvolimab Biosimilar is currently being evaluated as a research-grade antibody for potential use in the treatment of various cancers. CD117 is overexpressed in many types of cancer, including gastrointestinal stromal tumors (GIST), acute myeloid leukemia (AML), and melanoma. Therefore, Barzolvolimab Biosimilar has the potential to be used as a targeted therapy for these cancers. Additionally, preclinical studies have shown that this antibody can enhance the effects of chemotherapy and radiation therapy, making it a promising candidate for combination therapy.

In addition to its potential therapeutic applications, Barzolvolimab Biosimilar can also be used as a research tool to study the role of CD117 in cancer and other diseases. By specifically targeting CD117, researchers can gain a better understanding of its function and its potential as a therapeutic target. This antibody can also be used for diagnostic purposes, such as detecting CD117 expression in cancer cells.

Conclusion

Barzolvolimab Biosimilar, also known as Anti-CD117 mAb, is a monoclonal antibody that targets the CD117 protein, a receptor expressed on the surface of various cells, including cancer cells. Its structure, consisting of two heavy chains and two light chains, allows it to bind specifically to CD117 and activate immune cells to attack cancer cells. This antibody is currently being evaluated as a research-grade therapeutic option for various cancers and has the potential to be used in combination with other treatments. It also has applications in research and diagnostics, making it a valuable tool in the study of CD117 and its role in disease. Overall, Barzolvolimab Biosimilar shows great promise as a potential treatment for cancer and has the potential to improve patient outcomes in the future.

SDS-PAGE for Barzolvolimab Biosimilar - Anti-CD117 mAb

Barzolvolimab Biosimilar - Anti-CD117 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.